A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

The abnormal activation of epidermal growth factor receptor (EGFR) drives the development of non-small cell lung cancer (NSCLC). The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bin, Zeng, Fanjun, Deng, Jialong, Yao, Lintong, Liu, Shengbo, Hou, Hengliang, Huang, Yucheng, Zhu, Hongyuan, Wu, Shaowei, Li, Qiaxuan, Zhan, Weijie, Qiu, Hongrui, Wang, Huili, Li, Yundong, Yang, Xianzhu, Cao, Ziyang, Zhang, Yu, Zhou, Haiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140750/
https://www.ncbi.nlm.nih.gov/pubmed/37122898
http://dx.doi.org/10.1016/j.bioactmat.2023.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140750/
https://www.ncbi.nlm.nih.gov/pubmed/37122898
http://dx.doi.org/10.1016/j.bioactmat.2023.04.005

Ejemplares similares